Complications of hepatic artery infusion: a review of 4580 reported cases.
OBJECTIVE
The resurgence of hepatic artery infusion (HAI) for the treatment of colorectal liver metastases has been dampened by concern over its complications. We have reviewed the incidence and frequency of complications associated with HAI and discussed the factors associated with these complications.


METHODS
A PUBMED search was conducted from 1950-2001 using various combinations of these keywords: hepatic arterial infusion, colorectal carcinoma, complications, and trials. The main inclusion criterion was the reporting of HAI complications. The main exclusion criterion was duplicated patients. Extracted data included chemotherapeutic agents, catheter technique, drug toxicities, and catheter related complications. Relative risks and 95% confidence intervals were calculated.


RESULTS
We reviewed 437 articles/abstracts and included 101 studies. 4580 patients with 4582 toxicities and complications were reported. The mortality rate was 1%. The most common toxicities were: GI symptoms 22%, chemical hepatitis 19%, and bone marrow toxicity 8%. 5-fluorouracil (5-FU) HAI had statistically significant risk for GI symptoms and bone marrow toxicity. Floxuridine (FUDR) HAI had statistically significant risk for chemical hepatitis, sclerosing cholangitis, and biliary toxicity. The most common catheter complications were: hepatic artery occlusion 6%, catheter thrombosis 5%, and catheter displacement 7%.


CONCLUSIONS
This literature review of the complications of HAI confirms a low mortality associated with HAI. Sclerosing cholangitis and chemical hepatitis are associated with the use of FUDR, while the use of 5-FU is associated with bone marrow toxicity. Our observations support the development of hepatic cytoprotective agents and other effective anti-tumor agents to improve the results and morbidity of HAI for colorectal liver metastases.
Barnett
K T
KT
Department of Surgery, Southern Illinois University School of Medicine, Springfield, IL 62794-9638, USA.
Malafa
M P
MP
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D001157:Arterial Occlusive Diseases / Q000209:etiology; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002408:Catheters, Indwelling / Q000009:adverse effects; D015209:Cholangitis, Sclerosing / Q000209:etiology; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D004066:Digestive System Diseases / Q000139:chemically induced; D005467:Floxuridine / Q000008:administration & dosage / Q000009:adverse effects*; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D005548:Foreign-Body Migration / Q000209:etiology; D006499:Hepatic Artery; D006505:Hepatitis / Q000209:etiology; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects* / Q000379:methods; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D013927:Thrombosis / Q000209:etiology
D000964:Antimetabolites, Antineoplastic; D005467:Floxuridine; D005472:Fluorouracil